Combination Therapy Shown As Effective For Higher-Risk MDS/AML Patients
A phase two study that investigated the potential of the drugs azacitidine (AZA) and lenalidomide (LEN), demonstrated that the two therapies in combination may be an effective frontline treatment regimen for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 7, 2014 Category: Cancer & Oncology Source Type: news

Studies Find Detectable Pre-cancerous State in the Blood
Researchers from the Broad Institute of MIT and Harvard, Harvard Medical School, and Harvard-affiliated hospitals have uncovered an easily detectable, "pre-malignant" state in the blood that significantly increases the likelihood that an individual will go on to develop blood cancers such as leukemia, lymphoma, or myelodysplastic syndrome. The discovery, which was made independently by two research teams affiliated with the Broad and partner institutions, opens new avenues for research aimed at early detection and prevention of blood cancer. Findings from both teams appear this week in the New England Journal of ...
Source: Disabled World - November 27, 2014 Category: Disability Tags: Treatments Source Type: news

Two studies identify a detectable, pre-cancerous state in the blood
(Broad Institute of MIT and Harvard) Researchers from the Broad Institute, Harvard Medical School, and Harvard-affiliated hospitals have uncovered an easily detectable, 'pre-malignant' state in the blood that significantly increases the likelihood that an individual will go on to develop blood cancers such as leukemia, lymphoma, or myelodysplastic syndrome. The discovery, which was made independently by two research teams affiliated with the Broad and partner institutions, opens new avenues for research aimed at early detection and prevention of blood cancer. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - November 26, 2014 Category: Biology Source Type: news

Moffitt Cancer Center announces development of experimental treatment for myelodysplastic syndromes
(H. Lee Moffitt Cancer Center & Research Institute) In a major step to treat patients living with Myelodysplastic Syndromes, a group of diseases that affect the bone marrow and blood, Moffitt Cancer Center today announced the development of an innovative investigational biologic agent that could improve patient response and outcomes for MDS and other diseases. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 18, 2014 Category: Cancer & Oncology Source Type: news

Geron lands potential $900M blood cancer drug deal with J&J
Geron Corp. will hand over its experimental blood cancer drug imetelstat to Johnson & Johnson's Janssen Biotech Inc. unit for $35 million upfront, the Menlo Park company said Thursday. The deal ultimately could be worth $900 million if certain development, regulatory and commercial milestones are hit over several years. Janssen will lead mid-stage studies of the drug in myelofibrosis, myelodysplastic syndrome and acute myelogenous leukemia. Development costs for the two studies in myelofibrosis,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 13, 2014 Category: Biotechnology Authors: Ron Leuty Source Type: news

Geron lands potential $900M blood cancer drug deal with J&J
Geron Corp. will hand over its experimental blood cancer drug imetelstat to Johnson & Johnson's Janssen Biotech Inc. unit for $35 million upfront, the Menlo Park company said Thursday. The deal ultimately could be worth $900 million if certain development, regulatory and commercial milestones are hit over several years. Janssen will lead mid-stage studies of the drug in myelofibrosis, myelodysplastic syndrome and acute myelogenous leukemia. Development costs for the two studies in myelofibrosis,… (Source: bizjournals.com Health Care:Hospitals headlines)
Source: bizjournals.com Health Care:Hospitals headlines - November 13, 2014 Category: Hospital Management Authors: Ron Leuty Source Type: news

Moffitt, M2Gen tapped to coordinate central laboratory, biorepository services for MDS
(H. Lee Moffitt Cancer Center & Research Institute) Moffitt Cancer Center and M2Gen have been awarded a contract from the National Institutes of Health's National Heart, Lung, and Blood Institute to serve as the Central Laboratory and Biorepository for The National Myelodysplastic Syndromes Natural History Study (The National MDS Study). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 5, 2014 Category: Cancer & Oncology Source Type: news

M2Gen sets benchmark with $7.3M federal contract
Moffitt Cancer Center and M2Gen will play a central role in a new study of a group of blood disorders. The National Institutes of Health's National Heart, Lung, and Blood Institute awarded Moffitt and its for-profit subsidiary, M2Gen, a contract to serve as the Central Laboratory and Biorepository for The National Myelodysplastic Syndromes Natural History Study. The $7.3 million project is the first federally funded contract for biorepository services at M2Gen, Moffitt's for-profit subsidiary,… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 4, 2014 Category: American Health Authors: Margie Manning Source Type: news

A New Cancer Drug Worked In Over 25% Of Patients. What Does That Mean?
A new cancer drug, during a phase I trial, placed a patient with myelodysplastic syndrome in a complete remission that has lasted for more than three years. And it did so, in a non-invasive manner, setting forth a new way of treating cancer. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 10, 2014 Category: Pharmaceuticals Authors: Jon Fortenbury Source Type: news

FDA News Roundup: Merck, UCB, Pfizer, Ipsen, And More
In the news this week, the FDA recently approved the first immunotherapy for melanoma, as well as drugs for epilepsy and myelodysplastic syndrome. The FDA also cleared several drugs for new indications, QIDP status, and orphan drug status. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - September 8, 2014 Category: Pharmaceuticals Source Type: news

Study identifies gene network behind untreatable leukemia, possible treatment target
Researchers have identified a genetic/molecular network that fuels a high-risk and aggressive form of acute myeloid leukemia and its precursor disease myelodysplastic syndrome -- providing a possible therapeutic strategy for an essentially untreatable form of the blood cancer. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 4, 2014 Category: Science Source Type: news

Study identifies gene network behind untreatable leukemia and possible treatment target
(Cincinnati Children's Hospital Medical Center) Researchers have identified a genetic/molecular network that fuels a high-risk and aggressive form of acute myeloid leukemia and its precursor disease myelodysplastic syndrome -- providing a possible therapeutic strategy for an essentially untreatable form of the blood cancer. Scientists from the Cancer and Blood Diseases Institute at Cincinnati Children's Hospital Medical Center report their results in a study posted online Sept. 4 by Cell Reports. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 4, 2014 Category: Cancer & Oncology Source Type: news

MEI completes patient enrolment in Pracinostat Phase II trial for Myelodysplastic Syndrome
US-based oncology firm MEI Pharma has completed enrolment in a Phase II clinical trial of its lead investigational drug candidate, Pracinostat, in combination with azacitidine, to treat patients with previously untreated intermediate-2 or high-risk m… (Source: Drug Development Technology)
Source: Drug Development Technology - September 4, 2014 Category: Pharmaceuticals Source Type: news

Boston Strategics begins Phase I trial of anti-cancer agent to treat haematologic malignancies
Boston Strategics (BSC) has started a Phase I clinical trial of Fujifilm's anti-cancer agent FF-10501 in the US to treat patients with advanced haematologic malignancies, such as relapsed or refractory high-risk myelodysplastic syndromes (MDS). (Source: Drug Development Technology)
Source: Drug Development Technology - September 2, 2014 Category: Pharmaceuticals Source Type: news

NHS England launches plan for a sustainable Cancer Drugs Fund
The amount pledged will give more patients access to innovative drugs not routinely available on the NHS. Two new drugs will now also be added to the Fund: enzalutamide for prostate cancer and lenalidomide for a group of patients with myelodysplastic syndrome, a rare blood condition. With an annual budget of £200m, now rising by 40 per cent to £280m, the Fund has delivered important benefits for more than 55,000 patients since it began in 2010. More .... (Source: NHS Networks)
Source: NHS Networks - August 29, 2014 Category: UK Health Authors: Maria Axford Source Type: news

NICE recommends Celgene’s Revlimid to treat myelodysplastic syndromes
The UK National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Celgene's Revlimid (lenalidomide) to treat myelodysplastic syndromes (MDS). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 21, 2014 Category: Pharmaceuticals Source Type: news

New NICE position on lenalidomide
NICE has issued final draft guidance recommending lenalidomide as an option for treating myelodysplastic syndromes. (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 20, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Haematology celgene Latest News lenalidomide myelodysplastic syndromes nice revlimid Source Type: news

NICE recommends lenalidomide for treating blood disorders
NICE has issued final draft guidance recommending lenalidomide, an immunomodulatory drug also known as Revlimid, as an option for treating myelodysplastic syndromes (MDS). (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - August 20, 2014 Category: Nursing Source Type: news

Exposure to inflammatory bowel disease drugs could increase leukemia risk
(American Gastroenterological Association) Immunosuppressive drugs called thiopurines have been found to increase the risk of myeloid disorders, such as acute myeloid leukemia and myelodysplastic syndrome, a rare bone marrow disorder, seven-fold among inflammatory bowel disease patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 6, 2014 Category: Cancer & Oncology Source Type: news

GSK initiates Phase III trial of eltrombopag-azacitidine combination in MDS patients
GlaxoSmithKline (GSK) has initiated a Phase III trial, SUPPORT (TRC112121), of eltrombopag in patients with myelodysplastic syndromes (MDS), a type of cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - June 26, 2014 Category: Pharmaceuticals Source Type: news

GSK announces the start of a phase III study with eltrombopag in patients with myelodysplastic syndromes
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the start of a Phase III study, SUPPORT (TRC112121), to evaluate the platelet supportive care effects of eltrombopag (Promacta™/Revolade™). (Source: GSK news)
Source: GSK news - June 25, 2014 Category: Pharmaceuticals Source Type: news

Myelodysplastic Syndrome - Mayo Clinic videos
What is Myelodysplastic Syndrome (MDS)? Raoul Tibes, M.D., Ph.D., hematologist at Mayo Clinic in Arizona, provides an overview of myelodysplastic syndrome (MDS) including the symptoms and diagnosis.Myelodysplastic Syndrome Treatment. Raoul Tibes, M.D., Ph.D. discusses various treatment options available for individuals diagnosed with myelodysplastic syndrome. Posted at Clinical Cases and Images. Stay updated and subscribe, follow us on Twitter and connect on Facebook. (Source: Clinical Cases and Images)
Source: Clinical Cases and Images - June 5, 2014 Category: Journals (General) Tags: Hematology Mayo Clinic Oncology Source Type: news

Cyclacel Pharmaceuticals Provides Update on Its Clinical Development Plan of Sapacitabine for Myelodysplastic Syndromes (MDS)
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - June 1, 2014 Category: Pharmaceuticals Source Type: news

Clinical Advisory: Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN 0901)
Source: National Cancer Institute, National Heart, Lung, and Blood Institute - Related MedlinePlus Pages: Acute Myeloid Leukemia, Bone Marrow Transplantation, Myelodysplastic Syndromes (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 15, 2014 Category: Consumer Health News Source Type: news

Genetic tracking identifies cancer stem cells in human patients
The gene mutations driving cancer have been tracked for the first time in patients back to a distinct set of cells at the root of cancer -- cancer stem cells. The international research team studied a group of patients with myelodysplastic syndromes -- a malignant blood condition which frequently develops into acute myeloid leukemia. The researchers say their findings offer conclusive evidence for the existence of cancer stem cells. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 15, 2014 Category: Science Source Type: news

Scientists Get Closer to the Stem Cells That May Drive Cancers
Researchers say a rare and unique tumor cell appears to help a form of blood cancer mutate and spread Source: HealthDay Related MedlinePlus Pages: Cancer, Myelodysplastic Syndromes, Stem Cells (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 15, 2014 Category: Consumer Health News Source Type: news

Genetic tracking identifies cancer stem cells in human patients
(University of Oxford) The gene mutations driving cancer have been tracked for the first time in patients back to a distinct set of cells at the root of cancer -- cancer stem cells. The international research team, led by scientists at the University of Oxford and the Karolinska Institutet in Sweden, studied a group of patients with myelodysplastic syndromes -- a malignant blood condition which frequently develops into acute myeloid leukemia. The researchers say their findings offer conclusive evidence for the existence of cancer stem cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 15, 2014 Category: Cancer & Oncology Source Type: news

Kyowa HK Applies For Additional Indication Of NESP In Japan
Kyowa Hakko Kirin announced that is seeking approval from the Japanese Ministry of Health, Labor, and Welfare (MHLW) for additional indication of NESP Injection Plastic Syringe (NESP) for anemia with myelodysplastic syndrome. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - April 2, 2014 Category: Pharmaceuticals Source Type: news

Common blood cancer may be initiated by single mutation in bone cells
(Columbia University Medical Center) AML is a blood cancer, but for many patients the cancer may originate from an unusual source: a mutation in their bone cells. In a study published today in the online edition of Nature, researchers at Columbia University Medical Center found that a mutation in the bone cells called osteoblasts, which build new bone, causes AML in mice. The mutation was found in nearly 40 percent of patients with AML or myelodysplastic syndrome, a precursor condition, who were examined as part of the study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 21, 2014 Category: Cancer & Oncology Source Type: news

What scientific idea is ready for retirement?
Each year a forum for the world's most brilliant minds asks one question. This year's drew responses from such names as Richard Dawkins, Ian McEwan and Alan Alda. Here, edge.org founder John Brockman explains how the question came into being and we pick some of the best responsesEdge.org was launched in 1996 as the online version of "the Reality Club", an informal gathering of intellectuals who met from 1981 to 1996 in Chinese restaurants, artist lofts, investment banking firms, ballrooms, museums, living rooms and elsewhere. Though the venue is now in cyberspace, the spirit of the Reality Club lives on in the li...
Source: Guardian Unlimited Science - January 12, 2014 Category: Science Authors: The Observer Tags: Astronomy Biology Mathematics Technology Physics Features Internet Animal behaviour The Observer Science Source Type: news

Mechanism discovered that controls the development of myelodysplastic syndromes
Researchers at the Moffitt Cancer Center have discovered a control mechanism that can trigger the development of myelodysplastic syndromes (MDS), a group of blood cancers. This finding may lead to therapies capable of preventing the progression of these diseases.MDS primarily affects older individuals, with approximately 12,000 new cases diagnosed each year. In MDS, a person's blood is not able to make one or more types of healthy blood cells - red blood cells, white blood cells or platelets. Instead, the patient has a high number of immature stem cells that do not develop properly. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 24, 2013 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

Moffitt researchers discover mechanism controlling the development of myelodysplastic
(H. Lee Moffitt Cancer Center & Research Institute) Researchers at the Moffitt Cancer Center have discovered a control mechanism that can trigger the development of myelodysplastic syndromes, a group of blood cancers. This finding may lead to therapies capable of preventing the progression of these diseases. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 17, 2013 Category: Global & Universal Source Type: news

Sunesis Pharma starts Phase I/II myelodysplastic syndrome study
US-based Sunesis Pharmaceuticals has started an investigator-sponsored Phase I/II trial of vosaroxin in combination with azacitidine for the treatment of patients with myelodysplastic syndrome (MDS). (Source: Drug Development Technology)
Source: Drug Development Technology - December 12, 2013 Category: Pharmaceuticals Source Type: news

Access to transplants for MDS should not be limited by age
Patients with myelodysplastic syndromes (MDS) who were as old as 74 fared as well with stem cell transplantation as did patients in the 60-to-65 age range, according to a study from Dana-Farber Cancer Institute presented at the annual meeting of the American Society of Hematology."This is good evidence that age alone should not limit who should get a transplant for MDS," said Gregory Abel, MD, MPH, a medical oncologist at Dana-Farber. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 10, 2013 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

Age shouldn't limit access to transplants for MDS, study suggests
(Dana-Farber Cancer Institute) Patients with myelodysplastic syndromes who were as old as 74 fared as well with stem cell transplantation as did patients in the 60-to-65 age range, according to a study from Dana-Farber Cancer Institute presented at the annual meeting of the American Society of Hematology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 7, 2013 Category: Global & Universal Source Type: news

Chai Receives 2013 V Foundation MDS Grant
Li Chai, MD, associate medical director of Adult Transfusion Medicine in the Department of Pathology, was recently honored with the 2013 V Foundation MDS Grant for her research in targeting leukemic stem cell factors in myelodysplastic syndromes. (Source: BWH News)
Source: BWH News - November 21, 2013 Category: Hospital Management Source Type: news

Cornerstone pharmaceuticals receives FDA orphan drug designation of CPI-613 for treatment of myelodysplastic syndrome
Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CPI-613, the Company's lead Altered Energy Metabolism Directed (AEMD) drug candidate, for the treatment of myelodysplastic syndrome (MDS). MDS is a form of cancer that occurs when the blood-forming cells in the bone marrow are damaged, which leads to low numbers of one or more type of blood cells... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 7, 2013 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

Scientists erase brain tumor cells in mice
Scientists have discovered that a repurposed drug approved by the US Food and Drug Administration (FDA) is capable of erasing brain tumor cells in mice. This is according to a study published in the journal Oncotarget. Researchers from the Johns Hopkins University School of Medicine used a drug called 5-azacytidine - used to treat a pre-leukemia condition called myelodysplastic syndrome - to target a mutation in a gene previously identified in human brain tumors (gliomas) called isocitrate dehydrogenase 1 (IDH1)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 1, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Recognizing Familial Myeloid Leukemia in AdultsRecognizing Familial Myeloid Leukemia in Adults
Familial cases of adult myelodysplastic syndrome and acute myeloid leukemia are considered rare, but are likely to be more common than currently appreciated. Therapeutic Advances in Hematology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 27, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Dendritic Cells in Myelodysplastic SyndromesDendritic Cells in Myelodysplastic Syndromes
Dendritic cells are important regulators of immunity, but their role in myelodysplastic syndrome is unclear. Get the inside story. Immunotherapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 31, 2013 Category: Consumer Health News Tags: Allergy & Clinical Immunology Journal Article Source Type: news

Targeting Errant Immune System Enzyme Kills Myelodysplastic Cells
Scientists have successfully targeted a malfunctioning immune system enzyme to kill diseased cells from patients with myelodysplastic syndrome (MDS) - a blood disorder and precursor to leukemia. Reporting their results July 8 in Cancer Cell, researchers say their successful laboratory tests in human MDS cells and mouse models of MDS provide a molecular target for designing new drugs to battle a syndrome with few effective treatments... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 8, 2013 Category: Consumer Health News Tags: Immune System / Vaccines Source Type: news

Some Older Patients With Myelodysplastic Syndromes Benefit From Stem Cell Transplants
A new study by an international team led by Dana-Farber Cancer Institute scientists provides the first statistically-based guidelines for determining whether a stem cell transplant is appropriate for older patients with myelodysplastic syndromes (MDS) - the most common blood disorders in people over 60 years of age, and frequently a precursor for leukemia... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 25, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Stem Cell Therapy Best in Higher Risk MDS (CME/CE)
(MedPage Today) -- Reduced-intensity stem cell transplantation is the best treatment option for many patients in their 60s with intermediate-to-high-risk myelodysplastic syndrome (MDS), researchers found. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 25, 2013 Category: Hematology Source Type: news

Revlimid® indicated as a treatment for patients with rare form of blood disease
Celgene International Sàrl (NASDAQ: CELG) has been notified that the European Commission (EC) has amended the marketing authorisation for REVLIMID®. This decision means that REVLIMID is now approved to treat patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 19, 2013 Category: Drugs & Pharmacology Source Type: news

Safety and Efficacy of Deferasirox in Myelodysplastic SyndromeSafety and Efficacy of Deferasirox in Myelodysplastic Syndrome
Pumping too much iron? Will deferasirox help or harm your patients with MDS? Therapeutic Advances in Hematology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 27, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Onconova completes enrolment in Phase III study of rigosertib
Clinical-stage biopharmaceutical company Onconova Therapeutics has completed enrolment in its ONTIME pivotal Phase III study of rigosertib in patients with high-risk myelodysplastic syndromes. (Source: Drug Development Technology)
Source: Drug Development Technology - May 10, 2013 Category: Pharmaceuticals Source Type: news

Secondary Cancer Risk Found With Multiple Myeloma Maintenance Therapies
Multiple myeloma patients are at increased risk of developing myelodysplastic syndrome or acute leukemia after maintenance lenalidomide or thalidomide treatment, according to a new study. (Source: Cancer Network)
Source: Cancer Network - May 2, 2013 Category: Cancer & Oncology Source Type: news

Promising Phase I Clinical Trial Of Rogosertib Leads To Multi-Institutional Phase II Trial
Results of a phase 1 clinical trial reported at the American Association for Cancer Research (AACR) annual conference show that orally administered Rigosertib is well tolerated in patients with advanced solid tumors. This is the first trial in which orally administered Rigosertib, a dual kinase inhibitor, was studied in solid tumors. Intravenously rigosertib is already in phase 3 clinical trials for myelodysplastic syndrome and pancreatic cancer and oral rigosertib is being studied in a pair of Phase II trials in lower-risk transfusion dependent MDS patients... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 11, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Researchers Study Use Of Dasatinib For Patients With High-Risk Myelodysplastic Syndromes
Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides. The therapy may not be effective for all patients, but those with trisomy 8 chromosomal disorder have higher rates of stable disease and respond better to treatment with dasatinib, the study shows. Results of this study appeared in the March issue of Leukemia Research... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 25, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news